Clinical Research Directory
Browse clinical research sites, groups, and studies.
Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast Cancer
Sponsor: Peking Union Medical College Hospital
Summary
This is an observational cohort study. Investigators do not assign any intervention to participants. Chemotherapy was received in a completed clinical trial or is determined by the treating physicians as part of routine care, and study results will not be used to guide treatment. The study aims to identify clinicopathological and molecular features associated with outcomes after anthracycline-free or anthracycline-containing chemotherapy in women with high-risk, HER2-negative early breast cancer. Existing clinical and follow-up data and archived tumor tissue from participants of a trial completed at Peking Union Medical College Hospital (NCT01354522; enrollment ended in 2013) will be analyzed with gene expression, metabolic, and digital pathology methods to develop a prediction model. Tumor tissue remaining after routine surgery or biopsy will also be collected, with informed consent, from up to 50 additional patients for single-cell sequencing. All analyses are exploratory.
Official title: Individualized Anthracycline-Free Adjuvant Chemotherapy for High-Risk HER2-Negative Breast Cancer: Development of an Artificial Intelligence Prediction Model and Investigation of Metabolic Mechanisms Using Data and Archived Tissue From a Completed Clinical Trial
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2026-05-01
Completion Date
2027-12-01
Last Updated
2026-11-09
Healthy Volunteers
No
Interventions
Anthracycline-free chemotherapy
Received as part of routine clinical care or a previous trial; not assigned by this study.
Anthracycline-containing chemotherapy
Received as part of routine clinical care or a previous trial; not assigned by this study.
Locations (1)
Peking union medical college hospital
Beijing, China, China